Laboratory monkey prices in China have climbed to levels last seen during the COVID-19 pandemic [2].
The surge reflects a broader boom in new-drug research and development across the country. As biotech hubs in Beijing and other regions expand their clinical trials, the scarcity of available primates has created a high-cost environment for research organizations.
Joinn Laboratories, a Beijing-based contract research organization, is positioned to benefit significantly from this market shift. The company projects that its profit for the first half of the year will increase by more than 1,370% compared to the same period last year [1].
This financial growth is tied directly to the increased demand for laboratory monkeys used in the development of new pharmaceuticals [2]. The rise in prices indicates a tightening supply chain for animal models, which are essential for testing the safety, and efficacy of new drug candidates before they reach human trials.
Industry analysts said that the current demand mirrors the spikes seen during the pandemic era, though the current drivers are rooted in general pharmaceutical innovation rather than a specific global health crisis [2]. The cost of these animals is a critical overhead for biotech firms, meaning the price surge could influence the pace of drug discovery and the cost of future medications.
Joinn Laboratories continues to operate as a primary provider in this sector, leveraging its infrastructure to meet the needs of the expanding R&D landscape in China [1].
“Laboratory monkey prices in China have climbed to levels last seen during the COVID-19 pandemic.”
The dramatic profit forecast for Joinn Laboratories underscores the critical role of biological assets in the pharmaceutical pipeline. When the cost of essential research models like primates spikes, it creates a bottleneck for drug development. This trend suggests that China's biotech sector is experiencing a period of aggressive growth that is currently outpacing the biological supply chain, potentially increasing the cost of innovation for new therapies.
